New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:24 EDTILMN, NSM, RHHBY, VVUS, ATHN, SQNM, BAC, EPOCOn The Fly: Pre-market Movers
HIGHER: Epocrates (EPOC), up 22.6% after agreeing to be acquired by athenahealth (ATHN) for $11.75 per share, in cash... VIVUS (VVUS), up 9.6% after reporting strong growth in Qsymia prescriptions shipped to patients in December... Nationstar Mortgage Holdings (NSM), up 18.6% after confirming deal to acquire about $215B in mortgage servicing assets from Bank of America (BAC). Shares of BofA also up 0.7%... LOWER: Illumina (ILMN), down 9% after acquiring Verinata Health for $350M, Roche's (RHHBY) chairman reportedly says his company no longer looking to acquire Illumina... Sequenom's (SQNM), down 6.5% after reporting preliminary 2012 revenue, which William Blair says may be overshadowed by Illumina's acquisition of Verinata.
News For EPOC;ATHN;NSM;BAC;VVUS;ILMN;SQNM;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 30, 2015
05:30 EDTRHHBYGenentech reports ocrelizumab Phase III studies met primary, secondary endpoints
Subscribe for More Information
June 29, 2015
16:00 EDTBACOptions Update; June 29, 2015
Subscribe for More Information
09:35 EDTBACActive equity options trading on open
Subscribe for More Information
June 26, 2015
16:00 EDTBACOptions Update; June 26, 2015
Subscribe for More Information
June 25, 2015
16:00 EDTBACOptions Update; June 25, 2015
Subscribe for More Information
15:04 EDTBACNeuberger Berman buys management of PE fund of funds from BofA
Neuberger Berman announced that it has entered into an agreement with Merrill Lynch Alternative Investments, the alternative investment business of Bank of America whereby Neuberger Berman will acquire the management rights to certain Merrill Lynch traditional non-registered and 40-Act-registered private equity fund of funds. Merrill Lynch selected Neuberger Berman following an extensive due diligence process focused on private equity investment expertise, 40-Act capabilities and dedication to client service. Key private equity professionals from Merrill Lynch will be joining Neuberger Berman concurrent with the transaction. Terms of the deal are undisclosed. The transaction is expected to close in August.
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
09:34 EDTBACActive equity options trading on open
Active equity options trading on open: AAPL FB NFLX AMZN BAC CVX TWTR INTC GILD BBBY
09:27 EDTILMNLeerink life science tools analyst holds an analyst/industry conference call
Life Science Tools and Diagnostics Dan Leonard, along with Dr. Paul Robson and Dr. Peter Kuhn, discuss the demand for Fluidigm's single cell prep products, including the impact to Biomark and the utility of CyTOF on an Analyst/Industry conference call to be held on July 1 at 2 pm.
09:21 EDTILMNBioMed Realty leases build-to-suit laboratory in Cambridge to Illumina
BioMed Realty (BMR) announced that Illumina ILMN) has signed a 20-year lease for a 155,000 square foot new and innovative scientific research building in Cambridge, England. BioMed Realty acquired the land for the project from The Welding Institute under a long term ground lease, enlarging BioMed Realty's Granta Park campus in Cambridge, England.
07:13 EDTBACFed director says full transparency in stress testing can be 'enormous weakness'
Subscribe for More Information
June 24, 2015
16:00 EDTBACActionable Options for Wednesday, June, 24
iPath S&P 500 VIX Short-Term Futures up 30c to 17.32 Option volume leaders: AAPL FB NFLX BAC VALE MU BABA WMB T F EBAY FCX TWTR BBRY
09:07 EDTRHHBYCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:37 EDTBACDeutsche downgrades Citi, Goldman after share rallies
Deutsche Bank analyst Matt O'Connor recommends using the strong share performance of both Citi (C) and Goldman Sachs (GS) as on opportunity to take profits. The analyst this morning downgraded shares of both investment banks to Hold from Buy. Citi is up 21% from the lows on January 30 while Goldman is up 30% since July 1, 2014, the analyst points out. On Citi, O'Connor sees less near term upside with fixed income trading entering a seasonally weak period and core cost reductions largely over. On Goldman, the analyst sees a lack of catalysts to drive the stock meaningfully higher in the near term. His top picks among U.S. Banks are Bank of America (BAC), JPMorgan (JPM), M&T Bank (MTB) and SunTrust (STI).
June 23, 2015
16:00 EDTBACOptions Update; June 23, 2015
iPath S&P 500 VIX Short-Term Futures down 46c to 17. Option volume leaders: AAPL FB AAPL T BAC MU BTU WMB AMZN TWTR BBRY
09:36 EDTBACActive equity options trading on open
Subscribe for More Information
06:25 EDTBACBarclays-Stifel deal marks end of Lehman legacy, Business Insider reports
Subscribe for More Information
June 22, 2015
16:00 EDTBACOptions Update; June 22, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 17.45. Option volume leaders: AAPL FB BAC CHK WMB BABA TWTR MU AMBA TSLA JPM
10:36 EDTNSMNationstar management to meet with UBS
Meeting to be held in Dallas on June 23 hosted by UBS.
09:40 EDTBACActive equity options trading on open
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use